+Compare
NTLA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
2.74B

NTLA Price Prediction, Intellia Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for NTLA with price predictions
07:00 PM EST Dec 03, 2023

NTLA in upward trend: 10-day moving average moved above 50-day moving average on November 28, 2023

The 10-day moving average for NTLA crossed bullishly above the 50-day moving average on November 28, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NTLA's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 22, 2023. You may want to consider a long position or call options on NTLA as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on November 02, 2023. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

NTLA moved above its 50-day moving average on November 22, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where NTLA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NTLA entered a downward trend on November 17, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.655) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (329.397).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I. Advisor
published Earnings

NTLA is expected to report earnings to rise 6.52% to -147 cents per share on February 22

Intellia Therapeutics NTLA Stock Earnings Reports
Q4'23
Est.
$-1.47
Q3'23
Beat
by $0.12
Q2'23
Missed
by $0.08
Q1'23
Beat
by $0.23
Q4'22
Missed
by $0.02
The last earnings report on November 09 showed earnings per share of -137 cents, beating the estimate of -150 cents. With 1.30M shares outstanding, the current market capitalization sits at 2.74B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 26%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
598
Web
https://www.intelliatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EMECX9.50N/A
N/A
Ashmore Emerging Markets Equity C
PICEX6.77N/A
N/A
Virtus Vontobel Emerging Markets Opps C
GCVIX22.35N/A
N/A
Goldman Sachs Large Cp Val Insghts Instl
NZDJPY90.69-0.29
-0.31%
New Zealand Dollar - Japan Yen
GBPUSD1.26-0.01
-0.64%
United Kingdom Pound - United States Dollar

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with BEAM. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+0.16%
BEAM - NTLA
74%
Closely correlated
-0.03%
CRSP - NTLA
71%
Closely correlated
+4.17%
EDIT - NTLA
68%
Closely correlated
+2.60%
VCYT - NTLA
65%
Loosely correlated
-1.77%
DNLI - NTLA
64%
Loosely correlated
-1.05%
More